Neal C Bradsher
CIK 1278388 · last filed 2026-07-02
Neal C Bradsher is a corporate insider who has filed 100 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for LCTX, was dated Jul 2, 2026. Across all open-market trades the lifetime net is +$137.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $803.0M across reported positions. 226 SEC filings were submitted jointly with BROADWOOD CAPITAL INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$802.95M
12
100
$137.54M
Filer Profile
NEW YORK, NY 10019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LCTX | Director | 99,121,984 | $1.01 | $100.11M | $18.00M | 10 | 2026-07-02 |
| STAA | Director | 31,016,786 | $22.66 | $702.84M | $107.63M | 33 | 2026-06-22 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 54,558,508 | — | — | $10.50M | 23 | 2018-07-03 |
| BTX | 10%+ Owner | 0 | $8.87 | $0 | -$4.6K | 2 | 2017-09-18 |
| Insight Molecular Diagnostics Inc. (OCX) Delisted | 10%+ Owner | 305,668 | $3.20 | $978.1K | $0 | 1 | 2017-02-22 |
| Asterias Biotherapeutics, Inc. (AST.WS) Delisted | 7,399,696 | — | — | $0 | 1 | 2016-05-13 | |
| Asterias Biotherapeutics, Inc. (AST) Delisted | 3,282,050 | — | — | $0 | 1 | 2015-05-26 | |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Director | 5,478,320 | — | — | -$12.48M | 7 | 2014-01-31 |
| PALOMAR MEDICAL TECHNOLOGIES LLC (METH.A) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2013-06-26 |
| PALOMAR MEDICAL TECHNOLOGIES LLC (PMTI) Delisted | 10%+ Owner | 5,793,474 | — | — | $8.38M | 4 | 2012-11-16 |
| COMARCO INC (CMRO) Delisted | 10%+ Owner | 1,533,937 | — | — | $5.18M | 12 | 2008-04-25 |
| QUESTCOR PHARMACEUTICALS INC (QSC) Delisted | Director | 3,578,660 | — | — | $323.4K | 3 | 2008-01-03 |
Recent Filings
100 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2026-06-22 | STAA | Grant (A) | — | $0 | EDGAR |
| 2026-03-13 | STAA | Buy (P) | +2,010,639 | $36.80M | EDGAR |
| 2026-03-10 | STAA | Grant (A) | — | $0 | EDGAR |
| 2026-01-08 | STAA | Buy (P) | +1,219,959 | $26.45M | EDGAR |
| 2025-07-03 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2025-04-10 | STAA | Buy (P) | +561,681 | $8.60M | EDGAR |
| 2025-03-20 | STAA | Buy (P) | +605,532 | $10.76M | EDGAR |
| 2025-01-28 | LCTX | Buy (P) | +23,684,211 | $18.00M | EDGAR |
| 2024-07-03 | LCTX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.